TP53 ‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

IGHV@ 医学 威尼斯人 危险系数 内科学 胃肠病学 慢性淋巴细胞白血病 回顾性队列研究 肿瘤科 酪氨酸激酶抑制剂 无进展生存期 白血病 化疗 癌症 置信区间
作者
Hua-Jay J. Cherng,Raamis Khwaja,Rashmi Kanagal-Shamanna,Guilin Tang,Jan A. Burger,Philip J. Thompson,Alessandra Ferrajoli,Zeev Estrov,Koji Sasaki,Deepa Sampath,Xuemei Wang,Hagop M. Kantarjian,Michael J. Keating,William G. Wierda,Nitin Jain
出处
期刊:American Journal of Hematology [Wiley]
卷期号:97 (8): 1005-1012 被引量:3
标识
DOI:10.1002/ajh.26595
摘要

Long-term follow up of prospective studies has shown that continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy leads to durable remissions in previously untreated patients with TP53-altered chronic lymphocytic leukemia (CLL); however, it is unknown how variant allele frequency (VAF) of TP53 mutation (TP53-m) or percentage of cells with deletion of chromosome 17p [del(17p)] influences efficacy of firstline BTKi. We performed a retrospective analysis of 130 patients with CLL with baseline del(17p) and/or TP53-m treated with BTKi with or without the BCL2 inhibitor venetoclax (VEN) and with or without CD20 antibody in the firstline setting. A total of 104/130 (80%) patients had del(17p). TP53-m was noted in 89/110 (81%) patients tested; there were 101 unique TP53-m with an available VAF. The 4-year progression-free survival (PFS) and overall survival (OS) rates were 72.9% and 83.6%. No baseline characteristics including IGHV mutation status and number of TP53 alterations were associated with significant differences in PFS or OS, though a trend toward shorter PFS with increasing karyotypic complexity (hazard ratio 1.08, p = .066) was observed. Del(17p) was identified in <25% of cells in 26/104 (25%) of patients, and 28/101 (28%) of TP53-m were low-burden with a VAF of <10%; outcomes of these patients were similar to those with high-burden lesions. This study suggests that low-burden TP53 alterations should not be ignored when assessing genomic risk in CLL in the era of targeted therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
吐泡泡完成签到,获得积分10
刚刚
刚刚
小张想发刊完成签到,获得积分10
刚刚
明理的代容完成签到,获得积分10
刚刚
tanlaker完成签到,获得积分10
1秒前
lllppp发布了新的文献求助10
1秒前
火星天完成签到,获得积分10
1秒前
ohh完成签到,获得积分10
1秒前
1秒前
PhysicsXX完成签到,获得积分10
1秒前
隐形曼青的应助被mwx采纳,获得10
2秒前
2秒前
Jasper的应助被333采纳,获得10
2秒前
jie完成签到 ,获得积分10
2秒前
Janmy发布了新的文献求助10
3秒前
CipherSage的应助被贾贡献采纳,获得30
3秒前
3秒前
学习通完成签到,获得积分10
3秒前
张恒彬的爸爸完成签到,获得积分20
4秒前
4秒前
cl.发布了新的文献求助10
4秒前
大鱼完成签到,获得积分10
4秒前
麦当当发布了新的文献求助10
5秒前
5秒前
玉米完成签到,获得积分10
5秒前
害羞的不尤完成签到,获得积分10
5秒前
研友_VZG7GZ的应助被无聊的寒香采纳,获得10
5秒前
星空发布了新的文献求助10
6秒前
6秒前
学习通发布了新的文献求助10
6秒前
薛小飞发布了新的文献求助10
6秒前
大鱼发布了新的文献求助10
6秒前
摘星星完成签到,获得积分10
6秒前
Chambray完成签到,获得积分10
7秒前
spirit完成签到 ,获得积分10
7秒前
placebo完成签到,获得积分10
7秒前
8秒前
小左完成签到 ,获得积分10
8秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162